Opportunity Information: Apply for RFA AG 23 001

This NIH grant opportunity (RFA-AG-23-001) is an R01 research funding announcement focused on understanding how bilingualism may contribute to cognitive reserve and cognitive resilience during healthy aging and in the context of Alzheimer`s disease and related dementias (AD/ADRD). The central idea behind the announcement is that speaking more than one language might shape brain function in ways that help some people maintain thinking skills longer, delay noticeable symptoms, or cope better with underlying brain changes linked to aging and dementia. The FOA is aimed at moving the field beyond mixed or inconsistent findings by encouraging stronger, prospective, hypothesis-driven studies that can build a clearer theoretical framework for how second-language acquisition and bilingual experience affect the brain across the lifespan.

A major emphasis of the announcement is on carefully designed research that can identify the extent and the mechanisms of bilingualism`s impact on human brain function. In practice, this means proposals are expected to go beyond simple comparisons of bilingual versus monolingual groups and instead address key questions like which aspects of bilingual experience matter most (for example, age of acquisition, proficiency, frequency of use, language switching demands, literacy in both languages, or social context), which cognitive domains are affected (such as executive function, attention, memory, processing speed, or language control), and how these effects relate to established concepts of reserve and resilience. The FOA is also framed around the need to understand why some individuals appear to function well despite having brain pathology, and whether bilingualism contributes to that phenomenon in measurable, biologically plausible ways.

The announcement strongly encourages multimodal and multidisciplinary approaches, reflecting the view that bilingualism and cognitive aging are shaped by a complex mix of neural, environmental, and sociocultural factors. Competitive projects would likely integrate multiple types of data and expertise, such as neuropsychological testing, neuroimaging, and other biomarkers, along with detailed characterization of language history and use, educational and occupational experiences, and broader social determinants of health. The goal is not only to document correlations, but to clarify interactions and pathways, for example how bilingual experience may influence neural efficiency, functional connectivity, compensatory recruitment, or brain maintenance, and how those brain-level patterns relate to cognitive outcomes over time in aging and AD/ADRD.

From an administrative standpoint, this is a discretionary NIH grant using the R01 mechanism, listed under the health activity category with CFDA number 93.866. The FOA is labeled "Clinical Trial Optional," which means applicants may propose studies that include a clinical trial if appropriate, but a clinical trial is not required. The opportunity was created on 2021-10-26, with an original closing date of 2022-03-03. The source information does not specify an award ceiling or the expected number of awards in the provided fields, so applicants would typically rely on the full FOA text and NIH budget guidance for the most accurate funding expectations.

Eligibility is broad and includes many types of applicant organizations. Standard eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (outside of higher education); for-profit organizations (other than small businesses); and small businesses. The FOA also explicitly highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, non-U.S. entities (foreign organizations), regional organizations, tribal governments other than federally recognized ones, and U.S. territories or possessions. Taken together, this reflects a clear interest in supporting research that can include diverse populations and contexts, which is especially important for bilingualism research where language experience, migration history, education, and cultural factors can vary widely and strongly influence both exposure and outcomes.

In plain terms, NIH is looking for rigorous studies that can tell a more definitive story about whether, how, and for whom bilingualism helps protect thinking and memory in later life, and how that potential protection relates to Alzheimer`s and related dementias. Proposals that combine strong theory, careful measurement of bilingual experience, longitudinal or prospective designs when feasible, and multiple complementary methods are particularly well aligned with the intent of the announcement.

  • The National Institutes of Health in the health sector is offering a public funding opportunity titled "Understanding the Role of Bilingualism in Cognitive Reserve/Resilience in Aging and AD/ADRD (R01 Clinical Trial Optional)" and is now available to receive applicants.
  • Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
  • This funding opportunity was created on 2021-10-26.
  • Applicants must submit their applications by 2022-03-03. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
  • Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
Apply for RFA AG 23 001

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)

Previous opportunity: NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)

Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA AG 23 001

 

Applicants also applied for:

Applicants who have applied for this opportunity (RFA AG 23 001) also looked into and applied for these:

Funding Opportunity
Cellular Senescence Network: Murine Tissue Mapping Centers (U54 - Clinical Trial Not Allowed) Apply for RFA RM 22 003

Funding Number: RFA RM 22 003
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Potential New Care and Treatment (C&T) Health Activity. Apply for 72051722RFICT00001

Funding Number: 72051722RFICT00001
Agency: Dominican Republic USAID-Santo Domingo
Category: Health
Funding Amount: Case Dependent
Cellular Senescence Network: Technology Development and Application in Murine Systems (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA RM 22 005

Funding Number: RFA RM 22 005
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Cell-Specific Impact of Liquid-Liquid Phase Separation in Aging and AD/ADRD (R21 Clinical Trial Not Allowed) Apply for RFA AG 23 002

Funding Number: RFA AG 23 002
Agency: National Institutes of Health
Category: Health
Funding Amount: $275,000
Cellular Senescence Network: Technology Development and Application in Human Systems (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA RM 22 004

Funding Number: RFA RM 22 004
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional) Apply for PAR 22 053

Funding Number: PAR 22 053
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed) Apply for PAR 22 054

Funding Number: PAR 22 054
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Prodromal Synaptic and Circuit Changes that Contribute to AD/ADRD Onset and Progression (R01 Clinical Trial Not Allowed) Apply for PAR 22 059

Funding Number: PAR 22 059
Agency: National Institutes of Health
Category: Health
Funding Amount: $500,000
RePORT International Coordinating Center (RICC) (U01 Clinical Trial Not Allowed) Apply for RFA AI 21 078

Funding Number: RFA AI 21 078
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Transition to Aging Research for Predoctoral Students (F99/K00 Clinical Trial Not Allowed) Apply for RFA AG 22 026

Funding Number: RFA AG 22 026
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional) Apply for PAR 22 030

Funding Number: PAR 22 030
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed) Apply for PAR 22 028

Funding Number: PAR 22 028
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
NEI Regenerative Medicine Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed) Apply for PAR 22 070

Funding Number: PAR 22 070
Agency: National Institutes of Health
Category: Health
Funding Amount: $150,000
Data Harmonization, Curation and Secondary Analysis of Existing Clinical Datasets (R61/R33 Clinical Trial Not Allowed) Apply for PAR 22 055

Funding Number: PAR 22 055
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) Apply for PAR 22 047

Funding Number: PAR 22 047
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required) Apply for RFA MH 22 150

Funding Number: RFA MH 22 150
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Understanding Place-Based Health Inequalities in Mid-Life (R01 Clinical Trial Not Allowed) Apply for RFA AG 23 004

Funding Number: RFA AG 23 004
Agency: National Institutes of Health
Category: Health
Funding Amount: $400,000
NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) Apply for RFA HL 23 008

Funding Number: RFA HL 23 008
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Patient-Clinician Relationship: Improving Health Outcomes in Populations that Experience Health Care Disparities (R01 Clinical Trial Optional) Apply for PAR 22 064

Funding Number: PAR 22 064
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Age-related Macular Degeneration (AMD) Integrative Biology Initiative: Discovery of AMD Pathobiology using Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE) (U01 Clinical Trial Not Allowed) Apply for RFA EY 21 002

Funding Number: RFA EY 21 002
Agency: National Institutes of Health
Category: Health
Funding Amount: $250,000

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

Inside Our Applicants Portal

  • Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
  • Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
  • Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Access Applicants Portal

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Learn More

 

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 23 001", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.

 

Ask a Question: